Caroline Seymour

ctDNA shows promise in predicting recurrence risk and guiding adjuvant chemotherapy decisions in colon cancer.

RMC-9805 was proven safe and active in patients with previously treated, KRAS G12C–mutant pancreatic ductal adenocarcinoma.

RMC-9805 demonstrated a 30% objective response rate and 80% disease control rate in KRAS G12D–mutant PDAC patients.

Anita Scheuber, MD, PhD, details the mechanism of action of NDI-101150, early data seen with the agent, and next steps in the HPK1 inhibitor’s investigation.

Uproleselan combined with standard chemotherapy did not improve event-free survival in older AML patients in a phase 2 trial.

DE397 is the first MAT2A inhibitor to show clinical activity and safety in patients with MTAP-deletion urothelial cancer and non–small cell lung cancer.

For more first-hand insights, head over to our YouTube channel to watch Dr Markman discuss the inner workings of oncology: https://rb.gy/bvumdn.

The oncology community must reconsider its approach to defining optimal dosing and scheduling of antineoplastic agents.

David S. Miller, MD, discusses key efficacy, safety, and quality-adjusted survival data with selinexor in TP53 wild-type endometrial cancer.

Niraparib shows sustained progression-free survival benefit in ovarian cancer, despite no overall survival advantage, due to treatment crossover and multiple subsequent therapies.